

P24170.P01

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

13281 U.S. PTO

121703

<p>Attorney Docket No.      P24170      Total Pages</p>
Inventor(s) or Application Identifier: Viswanathan SRINIVASAN, Ralph BROWN, David BROWN, and Himanshu PATEL
Title: DOSAGE FORM CONTAINING PROMETHAZINE AND ANOTHER DRUG

ADDRESS TO:

Commissioner for Patents  
Mail Stop Patent Application  
PO Box 1450  
Alexandria, VA 22313-1450

APPLICATION ELEMENTS	ACCOMPANYING APPLICATION PARTS
<p>1. <input type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>a. <input type="checkbox"/> Small Entity Statement(s)</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages <u>37</u>] (preferred arrangement set forth below)            - Descriptive title of the Invention            - Cross References to Related Applications            - Statement Regarding Fed sponsored R &amp; D            - Reference to sequence listing, a table, or a computer program listing appendix            - Background of the Invention            - Brief Summary of the Invention            - Brief Description of the Drawings (if filed)            - Detailed Description            - Claim(s)            - Abstract of the Disclosure</p> <p>4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets <u>  </u>]</p> <p>5. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages <u>3</u>]            a. <input type="checkbox"/> Newly executed (original or copy) <input checked="" type="checkbox"/> Unexecuted            b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 20 completed)  <u>[Note Box 6 below]</u>            i. <input type="checkbox"/> DELETION OF INVENTOR(S)            Signed statement attached deleting inventor(s)            named in the prior application, see 37 CFR            1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked)            The entire disclosure of the prior application, from which a            copy of the oath or declaration is supplied under Box 5b, is            considered as being part of the disclosure of the accompanying            application and is hereby incorporated by reference therein.</p> <p>7. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p> <p>8. <input type="checkbox"/> CD-Rom or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>)</p>	<p>9. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)            a. <input type="checkbox"/> Computer Readable Form (CRF)            b. Specification Sequence Listing on:            i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or            ii. <input type="checkbox"/> paper            c. <input type="checkbox"/> Statements verifying identity of above copies</p> <p>10. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</p> <p>11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee)</p> <p>12. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>13. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>14. <input type="checkbox"/> Preliminary Amendment</p> <p>15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>16. <input type="checkbox"/> Figure of Drawing to be published _____</p> <p>17. <input type="checkbox"/> Foreign priority claimed            a. <input type="checkbox"/> Claim of Priority            b. <input type="checkbox"/> Certified Copy of Priority Document(s)</p> <p>18. <input checked="" type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i).            Applicant must attach form PTO/SB/35 or its equivalent.</p> <p>19. <input type="checkbox"/> Assignee: _____</p> <p>20. <input checked="" type="checkbox"/> Other: <u>Cover Letter Under 37 C.F.R. 1.53(b) and 1.53(f);</u>            _____            _____            _____            _____</p>
<p>21. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 C.F.R. 1.76:</p> <p><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior Application No. <u>  </u> / <u>  </u>, filed <u>  </u>.  <i>Prior application information: Examiner: _____</i></p>	

Address all future correspondence to Customer No. 7055 at the present address of:

GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

December 17, 2007

Date



Signature

Stephen M. Roylance, Reg. No. 31,296  
Typed or Printed Name

P24170.P02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Viswanathan SRINIVASAN et al.

Serial No. : Not Yet Assigned

Filed : Concurrently Herewith

For : DOSAGE FORM CONTAINING PROMETHAZINE AND ANOTHER DRUG

**COVER LETTER ACCOMPANYING U.S. PATENT APPLICATION  
FILED UNDER 37 C.F.R. 1.53(b) and 1.53(f)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
Sir:

Enclosed is a new patent application for filing in the U.S. Patent and Trademark Office under 37 C.F.R. 1.53(b) and 1.53(f) in which the appropriate filing fee is not included, and the attached Declaration and Power of Attorney are in unexecuted form.

The appropriate filing fee and a properly executed Declaration and Power of Attorney will be filed within the time period set forth in the Notice to File Missing Parts of Application, unless such time period has been extended by the filing of a petition accompanied by the extension fee under the provisions of 37 C.F.R. 1.136(a).

Related to the above, this application should be associated with Customer Number 7055, which includes the present correspondence address as follows:

GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191

The above-identified application includes:

- 37 pages of specification (including Abstract).
- 74 total claims with 5 independent.
- an unexecuted Declaration and Power of Attorney.

If there are any questions, please contact the undersigned at the below-listed telephone number.

Respectfully submitted,  
Viswanathan SRINIVASAN et al.



Stephen M. Roylance  
Reg. No. 31,296

December 17, 2003  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

P24170.P02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Viswanathan SRINIVASAN et al.

Serial No. : Not Yet Assigned

Filed : Concurrently Herewith

For : DOSAGE FORM CONTAINING PROMETHAZINE AND ANOTHER DRUG

**REQUEST FOR NON-PUBLICATION UNDER 37 C.F.R. 1.213**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicant hereby respectfully requests that the application not be published under 35 U.S.C. 122(b).

The undersigned hereby certifies that the invention disclosed in this application has not been and will not be the subject of an application filed in another country, or under multilateral international agreement, that requires publication at eighteen months after filing.

If any fees are required for consideration and/or entry of this non-publication request, the U.S. Patent and Trademark Office is hereby authorized to charge any additional fee, or credit any overpayment to Deposit Account No. 19-0089.

Should there be any questions, please contact the undersigned at the below listed telephone number

Respectfully submitted,  
Viswanathan SRINIVASAN et al.



Stephen M. Roylance  
Reg. No. 31,296

December 17, 2003  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191